Gauthier C, Langin D, Balligand J L
Laboratoire de Physiopathologie et Pharmacologie Cellulaires et Moléculaires, INSERM U533, CHU de Nantes and Faculté des Sciences et Techniques, Université de Nantes, France.
Trends Pharmacol Sci. 2000 Nov;21(11):426-31. doi: 10.1016/s0165-6147(00)01562-5.
beta-Adrenoceptors of the beta1 and beta2 subtypes classically mediate the effects of catecholamines on the contractility of cardiac muscle and the relaxation of vascular smooth muscle. Since the molecular characterization of the beta3-adrenoceptor in 1989, most studies of this adrenoceptor subtype have focused on its control of lipolysis in adipose tissues. However, more recent studies have investigated the involvement of beta3-adrenoceptors in the physiological control of cardiac and vascular contractility. In this article, the pharmacological and molecular evidence that supports the functional role of beta3-adrenoceptors in cardiovasculartissues of various species, including humans, will be discussed. These data might provide new insights into our understanding of the abnormal responsiveness of the cardiovascular system to catecholamines in heart failure and its treatment with beta3-adrenoceptor antagonists.
β1和β2亚型的β-肾上腺素能受体经典地介导儿茶酚胺对心肌收缩力和血管平滑肌舒张的作用。自1989年β3-肾上腺素能受体的分子特征被确定以来，对该肾上腺素能受体亚型的大多数研究都集中在其对脂肪组织中脂肪分解的控制上。然而，最近的研究已经调查了β3-肾上腺素能受体在心脏和血管收缩生理控制中的作用。在本文中，将讨论支持β3-肾上腺素能受体在包括人类在内的各种物种的心血管组织中发挥功能作用的药理学和分子证据。这些数据可能为我们理解心力衰竭时心血管系统对儿茶酚胺的异常反应性及其用β3-肾上腺素能受体拮抗剂治疗提供新的见解。
Zotero 插件